ID: ALA542832

Max Phase: Preclinical

Molecular Formula: C19H16ClF3N4O3

Molecular Weight: 404.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cl.NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1

Standard InChI:  InChI=1S/C19H15F3N4O3.ClH/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);1H

Standard InChI Key:  CIHZSSCESOLBRQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 404.35

Molecular Weight (Monoisotopic): 404.1096

AlogP: 2.04

#Rotatable Bonds: 3

Polar Surface Area: 101.45

Molecular Species: ZWITTERION

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.22

CX Basic pKa: 9.63

CX LogP: 0.47

CX LogD: 0.47

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.69

Np Likeness Score: -1.05

References

1. Rosen T, Chu DT, Lico IM, Fernandes PB, Shen L, Borodkin S, Pernet AG..  (1988)  Asymmetric synthesis and properties of the enantiomers of the antibacterial agent 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-1,4-dihydro-6- fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride.,  31  (8): [PMID:3397996] [10.1021/jm00403a017]

2. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

Source

Source(2):

• Scientific Literature
• SARS-CoV-2 Screening Data 2020-21